Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by Stockish12on Mar 24, 2021 4:06pm
368 Views
Post# 32868696

5 more days - my probabilities

5 more days - my probabilitiesBased on previous failed promises from this company, below are my probabilities

Aristotle launched before April 1 - 15% chance
Aristotle NOT launched before April 1 - 85% chance

This is not the first time this company has promised and failed. You remember last fins? (for those with a selective short memory lol) - company did a freaking PR and stated boldly that fins will be released on so so date. This did not come out until many days after the stated date. No communication whatsoever regarding the delay.

In my opinion, Aristotle will not launch before April 1, company will not provide any update regarding the delay. Price will dip below $1 and probably towards $0.70.

We will discuss this again on April 1. Then you will understand my continous reason why I maintain Tripp is the worst CEO to lead this company.
<< Previous
Bullboard Posts
Next >>